新肝模型用于研究α1-抗胰蛋白酶缺乏症
New liver model for studying alpha-1-antitrypsin deficiency
德国杜塞尔多夫大学和杜塞尔多夫大学医院的研究团队开发了一种基于诱导多能干细胞(iPSC)的肝细胞模型,用于研究α1-抗胰蛋白酶缺乏症(AATD)。该模型可帮助识别潜在的新治疗药物,其中两种化合物(suberoylanilide hydroxamic acid 和 carbamazepine)显示出减少细胞内累积AAT的效果。
AATD is a rare genetic metabolic disorder that affects the liver and lungs. A mutation causes liver cells (hepatocytes) to form misfolded alpha-1-antitrypsin (AAT). This misfolding results in reduced secretion of AAT into the blood plasma. AAT plays an important role in controlling inflammatory processes in the body by mitigating excessive reactions that lead to tissue damage.
When AAT levels are reduced, enzymes associated with inflammation can attack tissues in patients. This primarily affects the lungs and results in severe symptoms, such as coughing, shortness of breath or constriction of the airways. In some patients, liver function is also impaired as the misfolded AAT proteins can accumulate there and increase the susceptibility of the cells to stress reactions. These patients have a significantly increased risk of developing a liver tumor or cirrhosis. Research is currently being conducted into various potential forms of therapy. However, patients often need a liver transplant.
Research into potential new therapeutic approaches is impeded by the fact that there are very few models for a liver affected by AATD. A team from the Institute of Stem Cell Research and Regenerative Medicine at HHU and University Hospital Düsseldorf has therefore developed a model to make this easier in the future. Their research is published in the journal Stem Cell Research & Therapy.
First, they reprogrammed cells derived from two patients into induced pluripotent stem cells (iPSC). In the laboratory, these cells are capable of developing into cells of various organs. In contrast to the majority of established cell sources for such reprogramming, the researchers in Düsseldorf used urine as the starting material—an easily accessible source, which is readily available even in children or severely ill patients. The researchers succeeded in differentiating the iPSCs into hepatocytes.
They were able to demonstrate that the hepatocytes are also suitable for researching therapy options for AATD. The researchers examined four compounds for their effects on the disease mechanism, with two proving capable of reducing the amount of accumulated AAT in the cells. Both of these compounds—suberoylanilide hydroxamic acid (SAHA) and carbamazepine—are already established as therapies for other conditions.
SAHA is used in cancer therapy, while carbamazepine is used, for example, to treat focal epilepsy. Transcriptome analyses also revealed that chaperone expression increased during treatment with SAHA. These proteins support the folding of other proteins and may thus reduce the AAT accumulations.
"We were able to demonstrate that our model is suitable to study AATD and its therapy further," reports lead author PD Dr. Nina Graffmann (Institute of Stem Cell Research and Regenerative Medicine, UKD). "It not only helps us research new therapy options, but will also contribute in the future to improving our understanding of the course of the disease in young people and the possible involvement of the liver."
The study was carried out in collaboration with the researchers PD Dr. Malin Fromme and professor Pavel Strnad from University Hospital RWTH Aachen, the Medical University Lausitz—Carl Thiem (MUL-CT), Cottbus, and the Alpha1 liver center of Alpha1 Germany e.V.—the Society for Alpha-1 Antitrypsin Deficiency Patients.
"We are particularly delighted to be able to demonstrate in this joint study how research into rare diseases can benefit from collaboration across multiple locations," says Adjaye. "We would like to deepen this collaboration further in the future. We are already planning a follow-up study in which we are aiming to study the use of the new model more precisely."
More information
Nina Graffmann et al., SAHA increases chaperone expression and reduces Z-alpha-1-antitrypsin polymers in a patient specific iPSC-based liver model for alpha-1-antitrypsin deficiency, Stem Cell Research & Therapy (2026). DOI: 10.1186/s13287-026-05365-y
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New liver model for studying alpha-1-antitrypsin deficiency (2026, November 20) retrieved 20 November 2026 from https://medicalxpress.com/news/2026-11-liver-alpha-antitrypsin-deficiency.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com